🔴 Amneal Pharmaceuticals is trading 4.21% down in pre-market after cutting cash-flow guidance

Amneal Pharmaceuticals is trading $19.36, -4.21% in pre-market on November 4, following its Q3 results and reduced cash-flow guidance.

• It closed at $20.21 on November 3; it beat Q3 earnings and revenue expectations and raised its full-year outlook.
• Operating cash-flow guidance fell to $325–$375 million from $350–$400 million.
• A report said shares fell 3% immediately after results amid possibly elevated expectations; healthcare was up 1.55% pre-market, so sector direction did not explain the decline.